NCT01065662View on ClinicalTrials.gov

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

September 30, 2013

Study Completion Date

March 31, 2021

Conditions
Endometrial CancerOvarian CancerCervical CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

temsirolimus

Given on days 1, 8, 15 and 22 of each cycle

DRUG

cediranib

Taken orally daily

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

Susana M. Campos, MD

OTHER